Full-Time

Screening Sales Representative

Tucson, AZ

Posted on 11/23/2025

Exact Sciences

Exact Sciences

5,001-10,000 employees

Develops cancer screening and diagnostic tests

Compensation Overview

$79k - $118k/yr

+ Bonus

Company Does Not Provide H1B Sponsorship

Fort Huachuca, Sierra Vista, AZ, USA + 2 more

More locations: Central, AZ, USA | Tucson, AZ, USA

In Person

Daily local travel required; overnight travel may be required.

Category
Sales & Account Management (1)
Required Skills
Tableau
Excel/Numbers/Sheets
Requirements
  • Bachelor's degree in Sales, Business Management, Marketing or Science, or any other related field or 4 years relevant experience in lieu of degree.
  • 2+ years of previous sales, inside sales or account management experience OR 1+ years of previous sales experience plus 1+ years of experience in a healthcare setting or other field related to the essential duties of the role OR Completion of active-duty military service as a Junior Officer or above (Candidates may still be involved with military reserves).
  • Possession of a valid driver’s license; no suspended, revoked, surrendered, invalid, etc. allowed.
  • No more than two moving violations, events, or accidents within the last 36 months.
  • No alcohol or drug event in which a vehicle was driven by the candidate or employee, including but not limited to Blood Alcohol Content (BAC) failure, refusal to submit to alcohol or drug test, alcohol related suspension, etc. in the last 36 months.
  • No other results from the Motor Vehicle Report (MVR) check that exposes Exact Sciences to what Exact Sciences deems to be an unacceptable level of liability.
  • Ability to meet any requirements set by healthcare facilities for access to those facilities (e.g. vaccination requirements, mask requirements, etc.).
  • Demonstrated ability to perform the essential duties of the position with or without accommodation.
  • Authorization to work in the United States without sponsorship.
Responsibilities
  • Generate deep insight into local healthcare ecosystems and market landscape in order to identify opportunities to enhance the system of care and deliver improved patient outcomes through integration of Exact Science’s solutions.
  • Analyze the treatment journey across the local system of care in order to identify account opportunities to work with Health Care Professionals to improve clinical decision making and deliver better patient and population health outcomes in the context of EXAS current and future pipelines.
  • Build a network of relationships within accounts in order to gain insight into system, customer and patient unmet needs, including clinical stakeholders and administrators, and diligently captures information on customer interactions using the Customer Relationship Management (CRM) database, including point of contact (POC) information, sales call activities, market intelligence, funnel development and other data points.
  • Synthesize data from a range of formal and informal sources to understand the evolving and dynamic local care system, leveraging available tools and resources such as Engage (CRM), Excel, Tableau and available research to make data-driven decisions on account potential and opportunities in order to focus effort, including working across the Market team.
  • Create business and account plans based on opportunities to drive acceptance of Cologuard and other Exact Sciences solutions to enhance clinical decision making and the effectiveness of the system of care.
  • Lead the implementation of these business and customer plans to devise and implement customer-specific pre-and post-call engagement approaches that evaluate and address customer needs, in collaboration with a range of internal stakeholders including Screening Advocate (SA), Medical Affairs and Marketing.
  • Inform, educate and enable target physician and stakeholder groups about Exact Sciences products and value propositions to equip them to make informed decisions about treatment choices and patient resources and highlight the importance of screening to the customer, drawing on approved clinical studies and marketing aids.
  • Proactively drives business growth by focusing on customers with highest potential and proactively initiating connections to uncover unmet needs and opportunities.
  • Seeks regular feedback from customers about their experience, service, satisfaction and perceived value of working with Exact Sciences.
  • Leads the successful implementation of account plans through collaboration and coordination with key internal stakeholders to develop and execute strategies, enhance customers satisfaction, improve patient outcomes and business opportunities for Exact Sciences.
  • Ensures execution of targeted tactics to deliver business goals in coordination and orchestration with a wider range of internal cross-functional stakeholders, including Account Managers, Area Manager, Marketing, Sales Operations and Internal Sales Support.
  • Communicates a clear and compelling description of customer needs and opportunities to internal stakeholders in order to mobilize resources and shape solutions to address current and future customer needs.
  • Ensures that the team conducts business to the highest ethical and professional standards, consistent with Exact Sciences guidelines and policies and regulatory requirements and upholding the company mission and value through accountability, innovation, integrity, quality and teamwork.
Desired Qualifications
  • 2+ years of experience in sales of medical devices or diagnostics.
  • Experience working with primary care physicians targeted customers.
  • Background in commissioned, tangible product sales.
  • Expertise in computer technology that is specific to sales.
  • Proficiency in MS Excel, Word, Outlook and Customer Relationship Management (CRM) tool.
  • Ability to listen empathetically, understand information presented by people with different communication styles and different points of view, and mediate disagreements.
  • Effective organizational and proactive problem-solving skills.
  • Ability to work confidently in an environment of complexity and ambiguity.
  • Ability to create value for others through the presentation of new processes and concepts.
  • Able to productively and proactively contribute to a team environment, while demonstrating ability to manage workload and priorities independently.
  • Ability to function productively within a fast-paced, multi-tasking, entrepreneurial environment.
  • Ability to work on telephone and on a computer simultaneously.

Exact Sciences develops and sells cancer screening and diagnostic tests that aim to detect cancer at its earliest stages and inform treatment decisions. The tests are designed to analyze biological samples to identify cancer signals, enabling healthcare providers to screen patients, diagnose cancer earlier, and tailor therapies accordingly. The company differentiates itself through its global reach, collaborations with healthcare organizations, and a business model that centers on test sales and partnerships, not just standalone products. Its goal is to reduce the burden of cancer by improving early detection, enabling timely interventions, and supporting patients and clinicians with diagnostic information.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Madison, Wisconsin

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • Abbott merger closed March 23, 2026, adds $3B sales.
  • Walgreens partnership expands Cologuard via pharmacies nationwide.
  • Cancerguard advances multi-cancer early detection pipeline.

What critics are saying

  • Abbott integration delays Oncotype DX advancements, cuts growth 10-15%.
  • EPS dilution forces $75M Freenome R&D cuts, loses to Guardant.
  • Cultural clashes erase Exact Sciences brand, drops Oncotype preference 25%.

What makes Exact Sciences unique

  • Cologuard leads noninvasive colorectal cancer screening market.
  • Oncotype DX guides early-stage breast cancer treatment decisions.
  • Oncodetect detects MRD in triple-negative breast cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

Wellness Program

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

8%

2 year growth

8%
360Dx
Apr 20th, 2026
Exact Sciences broadens evidence for Oncodetect MRD test in early triple-negative breast cancer.

Exact Sciences broadens evidence for Oncodetect MRD test in early triple-negative breast cancer. SAN DIEGO - Exact Sciences, now part of Abbott, is continuing to build the evidence base supporting the use of its Oncodetect minimal residual disease (MRD) test in early-stage triple-negative breast cancer patients by demonstrating its ability to assess who is unlikely to achieve pathologic complete response after neoadjuvant treatment and at risk of distant recurrence. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Abbott
Mar 23rd, 2026
Abbott acquisition of Exact Sciences set to close on March 23, 2026

Abbott acquisition of Exact Sciences set to close on March 23, 2026. * Announcement follows receipt of all regulatory clearances necessary for closing * Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people ABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ - Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people. Together with Exact Sciences, Abbott will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages. "Proactively shaping the portfolio to anticipate future medical needs while building long-term shareholder value remains at the core of our strategic framework," said Robert B. Ford, chairman and chief executive officer, Abbott. "The addition of Exact Sciences enhances Abbott's growth profile and strengthens our leadership in diagnostics. This transaction brings a powerful new platform in cancer screening and diagnostics into Abbott, advancing our mission to make care more accessible and give people more control over their health." Strategic fit Exact Sciences is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor for recurrence. This acquisition strengthens Abbott's leadership position and capabilities in diagnostics, positioning the company to advance technologies that are more preventative, predictive and personalized. It expands Abbott's presence in one of the fastest-growing areas of healthcare as cancer incidence continues to rise worldwide. It also adds a new growth vertical to Abbott's already high-single-digit growth expectations, establishing leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments. Industry-leading offerings and pipeline Exact Sciences' product offerings include the Cologuard(R) test, a market-leading noninvasive colorectal cancer screening option; Oncotype DX(R), which informs personalized treatment decisions for patients with early-stage breast cancer; Oncodetect(R), a tumor informed molecular residual disease (MRD) test to help identify cancer recurrence and guide follow-up care; and Cancerguard(R), a multi-cancer early detection blood test. Exact Sciences is also advancing a leading pipeline of next-generation cancer diagnostics designed to detect cancer even earlier, optimize treatment decisions and enable regular monitoring to help people stay healthy and better manage disease. Financial As previously communicated, this transaction is expected to add approximately $3 billion of incremental sales in 2026, accelerate Abbott's 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per share (EPS) by approximately $0.20. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. Forward-Looking Statements This communication contains forward-looking statements about, among other things, the proposed acquisition of Exact Sciences by Abbott. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, the following: the possible inability of the parties to consummate the proposed transaction on a timely basis or at all; the possible inability of the parties to satisfy the conditions precedent to consummation of the proposed transaction on a timely basis or at all; the possible occurrence of any event, change or other circumstance that could give rise to the termination of the parties' definitive agreement for the proposed transaction; the ability of Abbott to successfully integrate Exact Sciences' operations, and the ability of Abbott to implement its plans, forecasts and other expectations with respect to Exact Sciences' business after the completion of the proposed transaction; risks relating to significant transaction costs associated with the proposed transaction and the possibility that the proposed transaction may be more expensive to complete than anticipated; risks related to the ability of Abbott to realize the anticipated synergies and benefits of the proposed transaction, including the possibility that the expected synergies and benefits from the proposed transaction will not be realized or will not be realized within the expected time period; potential adverse effects of the announcement or pendency of the proposed transaction; or any failure to complete the proposed transaction on the market price of Abbott's common stock, on the ability of Exact Sciences to develop and maintain relationships with its personnel (including Exact Sciences' ability to attract and retain highly qualified management and other scientific personnel) and customers, suppliers and others with whom it does business, or otherwise on Exact Sciences' or Abbott's business, financial condition, results of operations and financial performance; risks related to diversion of management's attention from Exact Sciences' ongoing business operations due to the proposed transaction; and the risk of litigation and/or regulatory actions related to the proposed transaction or Exact Sciences' business and the outcome of any such litigation or regulatory action. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Abbott and Exact Sciences described in the "Risk Factors" section in each of Abbott's Annual Report on Form 10-K for the year ended December 31, 2025, and Exact Sciences' Annual Report on Form 10-K for the year ended December 31, 2025, respectively, and their respective other reports filed with the SEC. Free copies of these documents may be obtained from the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abbott undertakes no obligation, and does not intend, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments or otherwise, except as required by law. SOURCE Abbott For further information: Abbott Media: Scott Stoffel, (224) 668-5201, Abbott Financial: Michael Comilla, (224) 668-1872

eNews Park Forest
Mar 13th, 2026
Workflow Services Supports Walgreens National Colorectal Cancer Initiative to Close Screening Gaps; Leverages Cologuard(R) Tests to Expand Reach

Workflow Services supports Walgreens national Colorectal Cancer initiative to close screening gaps; leverages Cologuard(R) tests to expand reach. PR Newswire Today at 9:39pm PDT PR Newswire MADISON, Wis., March 13, 2026 MADISON, Wis., March 13, 2026 /PRNewswire/ - Beginning today, Walgreens customers can access tools and resources to better understand their colorectal cancer screening options - including a streamlined pathway that enables eligible, average-risk patients to request screening with the Cologuard(R) test. In recognition of Colorectal Cancer Awareness Month and to help remove barriers to screening and support earlier detection of colorectal cancer, when it is most treatable, Walgreens is working to increase awareness of non-invasive screening options by teaming up with Exact Sciences, the maker of Cologuard, and Workflow Services, a pharmacy clinical workflow platform that integrates screening programs directly into pharmacy operations. Colorectal cancer is often called a "silent" disease because it frequently develops without symptoms. It is expected to claim more than 55,000 lives in the U.S. this year alone and has become the #1 cause of cancer death in adults under 50.[1,2] Colorectal cancer is also highly preventable.[3] Screening for colorectal cancer can help find pre-cancerous growths (polyps) so they can be removed before they turn into cancer. When caught in its early stages, the five-year survival rate is 91%.[4] Unfortunately, more than 1 in 3 U.S. adults are not up to date with colorectal screening.[5] By launching this program, Walgreens is taking an important step toward closing the screening gap and supporting earlier detection for millions of Americans. The Cologuard test is an FDA-approved, non-invasive stool DNA test to screen adults 45 and older at average risk for colorectal cancer. It offers an effective way to screen from home, requiring no special diet, no prep, and no time away from work. It is also covered by most insurance companies, including Medicare and Medicaid. "As a trusted health partner in the community, we have a unique opportunity to change the trajectory of this disease," said Rick Gates, Chief Pharmacy Officer, Walgreens. "We are offering eligible patients' education around their colon cancer screening options and giving them access to take action. Use-at-home stool-based tests like Cologuard allow customers to prioritize their health in a convenient way. By making screening a seamless part of the pharmacy experience, we are helping our patients take proactive, life-saving action." Workflow Services, a software platform to support clinical service delivery in pharmacies, has partnered with Walgreens and Exact Sciences to bring a nationwide colorectal cancer screening program to close care gaps for their customers. As pharmacies continue to evolve into important access points for clinical services, Workflow Services is proud to help enable scalable, pharmacist-led care programs that improve patient access and health outcomes. Access to preventative screenings is just another way Walgreens serves as a connector between patients, caregivers, providers, and payers, to address health barriers. "Exact Sciences is proud to support Walgreens in this preventative health initiative to increase screening rates," said Jake Orville, Executive Vice President and General Manager of Screening, Exact Sciences. "Cologuard tests have made a significant positive impact on screening uptake in the United States and this effort represents an exciting new way to bring the opportunity to screen to patients via their local pharmacy." To learn more about Cologuard tests and colorectal cancer screening options, patients and customers can visit: Cologuard - Noninvasive Colon Cancer Screening | Find Care About Walgreens Founded in 1901, Walgreens (www.walgreens.com) proudly serves more than 9 million customers and patients each day across its nearly 8,000 stores throughout the U.S. and Puerto Rico. Walgreens has approximately 211,000 team members, including roughly 85,000 healthcare service providers, and is committed to being the first choice for pharmacy, retail and health services, building trusted relationships that create healthier futures for customers, patients, team members and communities. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard(R) and Oncotype DX(R), along with innovative solutions like the Cancerguard(R) test for multi-cancer early detection and the Oncodetect(R) test for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook. About Workflow Services Workflow Services is a software platform that helps pharmacies unlock their full potential as community healthcare destinations. Learn more at www.workflowservices.com References * American Cancer Society. Cancer Facts & Figures 2026. Atlanta: American Cancer Society; 2026 * Siegel RL, Wagle NS, Jemal A. Leading Cancer Deaths in People Younger Than 50 Years. JAMA. 2026;335(7):632-634. doi:10.1001/jama.2025.25467 * Itzkowitz SH. Incremental advances in excremental cancer detection tests. J Natl Cancer Inst. 2009;101(18):1225-1227. * Survival rates for colorectal cancer. American Cancer Society. Updated January 29, 2024. Accessed October 9, 2025. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html * Cancer Prevention & Early Detection Facts & Figures, 2025-2026. American Cancer Society. 2025. https://www.cancer.org/research/cancer-facts-statistics/cancer-prevention-early-detection.html SOURCE Workflow Services This is a paid placement. For further inquiries, please contact PR Newswire directly.

Business Wire
Mar 4th, 2026
KeyCare Raises $27.4 Million to Scale their AI-Powered, Epic-Based Virtual Care Solution for Health Systems

KeyCare, the nation’s first Epic-based virtual care company, today announced the close of a $27.4M financing round. The most recent round was led by HealthX ...

Yahoo Finance
Mar 3rd, 2026
KeyCare raises $27.4M to scale AI-powered Epic-based virtual care solution for health systems

KeyCare, the first Epic-based virtual care company, has raised $27.4 million in a financing round led by HealthX Ventures, bringing total capital raised to over $55 million. Participants include 8VC, LRVHealth, BOLD Capital Partners and strategic partners such as WellSpan Health, Allina Health and University of Chicago Ventures. The company operates a 24/7 virtual care medical group providing urgent, preventive, chronic and primary care whilst maintaining integration with patients' home health systems. KeyCare works on an optimised instance of Epic's platform to preserve continuity across the care journey. The funding will support AI-enabled technology development, operational expansion and platform scaling to improve patient experience and provider efficiency. KeyCare aims to create what industry observers call "Telehealth 2.0" by combining Epic's AI capabilities with proprietary AI development.

INACTIVE